These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prostaglandin E1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy.
    Author: Hoshi K, Mizushima Y, Kiyokawa S, Yanagawa A.
    Journal: Drugs Exp Clin Res; 1986; 12(8):681-5. PubMed ID: 3757764.
    Abstract:
    Lipo-PGE1 is a drug preparation of prostaglandin E1 (PGE1) incorporated in lipid microspheres similar in properties to liposomes. A randomized, single-blind, cross-over study comparing free PGE1 (PGE1 cyclodextrine, PGE1CD) with lipo-PGE1 was performed. Twenty patients with peripheral vascular diseases and diabetic neuropathy entered the trial. The first seven days' treatment was either 5 micrograms/day of lipo-PGE1 or 40 micrograms/day of PGE1CD, followed by a seven-day wash-out period; then cross-over was performed for another week's administration. Improvements were achieved by both PGE1 preparations. The comparison between lipo-PGE1 and PGE1CD showed that the former was significantly superior, both in final global improvement (p less than 0.01) and in terms of patients' preference (p less than 0.01); lipo-PGE1 also produced fewer side-effects. This study suggests that lipo-PGE1 is a very valuable agent for the treatment of peripheral vascular disorders and diabetic neuropathy.
    [Abstract] [Full Text] [Related] [New Search]